Selected article for: "clinical outcome and HLA allele"

Author: Littera, Roberto; Campagna, Marcello; Deidda, Silvia; Angioni, Goffredo; Cipri, Selene; Melis, Maurizio; Firinu, Davide; Santus, Simonetta; Lai, Alberto; Porcella, Rita; Lai, Sara; Rassu, Stefania; Scioscia, Rosetta; Meloni, Federico; Schirru, Daniele; Cordeddu, William; Kowalik, Marta Anna; Serra, Maria; Ragatzu, Paola; Carta, Mauro Giovanni; Del Giacco, Stefano; Restivo, Angelo; Deidda, Simona; Orrù, Sandro; Palimodde, Antonella; Perra, Roberto; Orrù, Germano; Conti, Maria; Balestrieri, Cinzia; Serra, Giancarlo; Onali, Simona; Marongiu, Francesco; Perra, Andrea; Chessa, Luchino
Title: Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
  • Cord-id: dk654vv0
  • Document date: 2020_12_4
  • ID: dk654vv0
    Snippet: AIM: SARS-CoV-2 infection is a world-wide public health problem. Several aspects of its pathogenesis and the related clinical consequences still need elucidation. In Italy, Sardinia has had very low numbers of infections. Taking advantage of the low genetic polymorphism in the Sardinian population, we analyzed clinical, genetic and immunogenetic factors, with particular attention to HLA class I and II molecules, to evaluate their influence on susceptibility to SARS-CoV-2 infection and the clinic
    Document: AIM: SARS-CoV-2 infection is a world-wide public health problem. Several aspects of its pathogenesis and the related clinical consequences still need elucidation. In Italy, Sardinia has had very low numbers of infections. Taking advantage of the low genetic polymorphism in the Sardinian population, we analyzed clinical, genetic and immunogenetic factors, with particular attention to HLA class I and II molecules, to evaluate their influence on susceptibility to SARS-CoV-2 infection and the clinical outcome. METHOD AND MATERIALS: We recruited 619 healthy Sardinian controls and 182 SARS-CoV-2 patients. Thirty-nine patients required hospital care and 143 were without symptoms, pauci-symptomatic or with mild disease. For all participants, we collected demographic and clinical data and analyzed the HLA allele and haplotype frequencies. RESULTS: Male sex and older age were more frequent in hospitalized patients, none of whom had been vaccinated during the previous seasonal flu vaccination campaignes. Compared to the group of asymptomatic or pauci-symptomatic patients, hospitalized patients also had a higher frequency of autoimmune diseases and glucose-6-phosphate-dehydrogenase (G6PDH) deficiency. None of these patients carried the beta-thalassemia trait, a relatively common finding in the Sardinian population. The extended haplotype HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01 [OR 0.1 (95% CI 0–0.6), Pc = 0.015] was absent in all 182 patients, while the HLA-C*04:01 allele and the three-loci haplotype HLA-A*30:02, B*14:02, C*08:02 [OR 3.8 (95% CI 1.8–8.1), Pc = 0.025] were more frequently represented in patients than controls. In a comparison between in-patients and home care patients, the HLA-DRB1*08:01 allele was exclusively present in the hospitalized patients [OR > 2.5 (95% CI 2.7–220.6), Pc = 0.024]. CONCLUSION: The data emerging from our study suggest that the extended haplotype HLA-A*02:05, B*58:01, C*07:01, DRB1*03:01 has a protective effect against SARS-CoV-2 infection in the Sardinian population. Genetic factors that resulted to have a negative influence on the disease course were presence of the HLA-DRB1*08:01 allele and G6PDH deficiency, but not the beta-thalassemic trait. Absence of influenza vaccination could be a predisposing factor for more severe disease.

    Search related documents:
    Co phrase search for related documents
    • activating signal and adaptive innate: 1, 2
    • activating signal and adaptive innate immunity: 1, 2
    • activity regulate and acute ards respiratory distress syndrome: 1
    • activity regulate and adaptive innate: 1, 2, 3, 4, 5, 6
    • activity regulate and adaptive innate immunity: 1
    • activity regulate and liver damage: 1, 2
    • acute ards respiratory distress syndrome and adaptive host immunity: 1
    • acute ards respiratory distress syndrome and adaptive host immunity innate: 1
    • acute ards respiratory distress syndrome and adaptive host innate: 1, 2
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome complication and liver damage: 1, 2
    • adaptive innate and liver damage: 1, 2, 3, 4
    • adaptive innate immunity and liver damage: 1, 2